Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 2
1993 4
1994 1
1995 3
1996 3
1997 1
1998 6
1999 2
2000 7
2001 2
2002 5
2003 5
2004 12
2005 2
2006 3
2007 6
2008 7
2009 5
2010 7
2011 4
2012 9
2013 9
2014 7
2015 10
2016 7
2017 5
2018 10
2019 8
2020 11
2021 12
2022 11
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

173 results
Results by year
Filters applied: . Clear all
Page 1
Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges.
Seijo LM, Peled N, Ajona D, Boeri M, Field JK, Sozzi G, Pio R, Zulueta JJ, Spira A, Massion PP, Mazzone PJ, Montuenga LM. Seijo LM, et al. Among authors: montuenga lm. J Thorac Oncol. 2019 Mar;14(3):343-357. doi: 10.1016/j.jtho.2018.11.023. Epub 2018 Dec 4. J Thorac Oncol. 2019. PMID: 30529598 Free PMC article. Review.
YES1 Is a Druggable Oncogenic Target in SCLC.
Redin E, Garrido-Martin EM, Valencia K, Redrado M, Solorzano JL, Carias R, Echepare M, Exposito F, Serrano D, Ferrer I, Nunez-Buiza A, Garmendia I, García-Pedrero JM, Gurpide A, Paz-Ares L, Politi K, Montuenga LM, Calvo A. Redin E, et al. Among authors: montuenga lm. J Thorac Oncol. 2022 Dec;17(12):1387-1403. doi: 10.1016/j.jtho.2022.08.002. Epub 2022 Aug 18. J Thorac Oncol. 2022. PMID: 35988891
Molecular biomarkers in early stage lung cancer.
Rodríguez M, Ajona D, Seijo LM, Sanz J, Valencia K, Corral J, Mesa-Guzmán M, Pío R, Calvo A, Lozano MD, Zulueta JJ, Montuenga LM. Rodríguez M, et al. Among authors: montuenga lm. Transl Lung Cancer Res. 2021 Feb;10(2):1165-1185. doi: 10.21037/tlcr-20-750. Transl Lung Cancer Res. 2021. PMID: 33718054 Free PMC article. Review.
Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis.
Ortiz-Espinosa S, Morales X, Senent Y, Alignani D, Tavira B, Macaya I, Ruiz B, Moreno H, Remírez A, Sainz C, Rodriguez-Pena A, Oyarbide A, Ariz M, Andueza MP, Valencia K, Teijeira A, Hoehlig K, Vater A, Rolfe B, Woodruff TM, Lopez-Picazo JM, Vicent S, Kochan G, Escors D, Gil-Bazo I, Perez-Gracia JL, Montuenga LM, Lambris JD, Ortiz de Solorzano C, Lecanda F, Ajona D, Pio R. Ortiz-Espinosa S, et al. Among authors: montuenga lm. Cancer Lett. 2022 Mar 31;529:70-84. doi: 10.1016/j.canlet.2021.12.027. Epub 2021 Dec 28. Cancer Lett. 2022. PMID: 34971753
Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.
Moutafi MK, Molero M, Martinez Morilla S, Baena J, Vathiotis IA, Gavrielatou N, Castro-Labrador L, de Garibay GR, Adradas V, Orive D, Valencia K, Calvo A, Montuenga LM, Ponce Aix S, Schalper KA, Herbst RS, Paz-Ares L, Rimm DL, Zugazagoitia J. Moutafi MK, et al. Among authors: montuenga lm. J Immunother Cancer. 2022 Aug;10(8):e004757. doi: 10.1136/jitc-2022-004757. J Immunother Cancer. 2022. PMID: 36002182 Free PMC article.
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.
Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M. Duruisseaux M, et al. Among authors: montuenga lm. Lancet Respir Med. 2018 Oct;6(10):771-781. doi: 10.1016/S2213-2600(18)30284-4. Epub 2018 Aug 9. Lancet Respir Med. 2018. PMID: 30100403 Free article.
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K. Gettinger S, et al. Among authors: montuenga lm. Cancer Discov. 2017 Dec;7(12):1420-1435. doi: 10.1158/2159-8290.CD-17-0593. Epub 2017 Oct 12. Cancer Discov. 2017. PMID: 29025772 Free PMC article.
DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity.
Valencia K, Echepare M, Teijeira Á, Pasquier A, Bértolo C, Sainz C, Tamayo I, Picabea B, Bosco G, Thomas R, Agorreta J, López-Picazo JM, Frigola J, Amat R, Calvo A, Felip E, Melero I, Montuenga LM. Valencia K, et al. Among authors: montuenga lm. J Exp Med. 2022 Dec 5;219(12):e20220726. doi: 10.1084/jem.20220726. Epub 2022 Sep 28. J Exp Med. 2022. PMID: 36169652
173 results